$115.03+4.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Just reported
From Rhythm Pharmaceuticals, Inc.'s results release of November 3, 2026; its quarterly report has since been filed.
Actual
$92.1M
+80% y/y
+29% q/q
Guided
—
No guide given
Actual
-$0.61
Guided
—
No guide given
Actual
-$39.3M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $92.1M | $51.3M | +79.59% |
| Profit | -$41.4M | -$52.9M | +21.80% |
| Profit per share | -$0.61 | -$0.82 | +25.61% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Rhythm Pharmaceuticals, Inc. reported on November 3, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Rhythm continues to make strong progress in bringing IMCIVREE ® (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
The quote and the company description come from Rhythm Pharmaceuticals, Inc.’s Item 2.02 8-K filed November 3, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.